

PHASE WISE DISTRIBUTION OF IMMUNOTHERAPEUTIC AGENTS



RAS LIFE SCIENCE SOLUTIONS

| anti PD-1 Inhibitors | Phase I | Phase II | Phase III | Approved |
|--|-------------|----------|-----------|----------|
| Nivolumab Bristol-Myers Squibb | | | | |
| BMS-936559 Bristol-Myers Squibb | | | | |
| Pembrolizumab MERCK INVENTING FOR LIFE | | | | |
| Spartalizumab NOVARTIS | | | | |
| Camrelizumab JIANG SU HENG RUI MEDICINE | | | | |
| Toripalimab Shanghai Junshi biosciences Co.,Ltd. | | | | |
| Sintilimab Lilly Innovent | | | | |
| Tislelizumab BeiGene Celgene | | | | |
| MEDI0680 MedImmune | | | | |
| Dostarlimab gsk TESARO | | | | |
| Cemiplimab REGENERON | | | | |
| Cetrelimab janssen | | | | |
| AGEN 2034 a genus | | | | |
| BCD 100 BIOCAD Biopharmaceutical Company | | | | |
| INMGA012 Incyte MACROGENICS | | | | |
| MGD013 MACROGENICS | | | | |
| CX-188 Bristol-Myers Squibb CYTOMX THERAPEUTICS | Preclinical | | | |

| anti PD-L1 Inhibitors | Phase I | Phase II | Phase III | Approved |
|--|---------|----------|-----------|----------|
| Durvalumab AstraZeneca | | | | |
| Avelumab Pfizer | | | | |
| Atezolizumab Genentech | | | | |
| CA-170 AURIGENE Accelerating Oncology CURIS | | | | |
| CK-301 CHECKPOINT THERAPEUTICS | | | | |
| FAZ053 NOVARTIS | | | | |
| LY3300054 Lilly | | | | |
| CX-072 CYTOMX THERAPEUTICS | | | | |